LYEL · NASDAQ
Lyell Immunopharma (LYEL) Stock Price & Fundamentals
Lyell Immunopharma (LYEL) closed at $779.15 on Oct 9, 2026, up 0.82% from the previous close of $772.80.
Share price, past year
1Y +17.39%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $779.15 |
| Sep 30, 2026 | $768.38 |
| Aug 31, 2026 | $761.21 |
| Jul 31, 2026 | $743.71 |
| Jun 30, 2026 | $707.53 |
| May 29, 2026 | $714.78 |
| Apr 30, 2026 | $726.85 |
| Mar 31, 2026 | $657.30 |
| Feb 27, 2026 | $684.06 |
| Jan 30, 2026 | $649.24 |
| Dec 31, 2025 | $669.48 |
| Nov 28, 2025 | $646.46 |
| Oct 31, 2025 | $688.36 |
Key statistics
- Market cap
- $18.23B
- P/E (TTM)
- —
- EPS (TTM)
- −$12.65
- Revenue (TTM)
- $27.00K
- Net income (TTM)
- −$248.48M
- Shares outstanding
- 23.4M
- Dividend yield
- —
- 52-week range
- $644.30 – $788.86
Lyell Immunopharma's market cap is $18.23B, based on a share price of $779.15 and 23.4M shares outstanding as of Jun 30, 2026.
Financials
Lyell Immunopharma reported revenue of $36.00K for fiscal 2025, down 40.98% from fiscal 2024.
Lyell Immunopharma reported a net loss of $274.45M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $36.00K | −41.0% | −$274.45M | −762,355.6% | −$16.06 | −$150.80M |
| FY2024ended Dec 31, 2024 | $61.00K | −53.1% | −$342.99M | −562,285.3% | −$26.23 | −$162.86M |
| FY2023ended Dec 31, 2023 | $130.00K | −99.9% | −$234.63M | −180,486.2% | −$18.70 | −$166.38M |
| FY2022ended Dec 31, 2022 | $84.68M | +695.2% | −$183.12M | −216.2% | −$14.80 | −$193.83M |
| FY2021ended Dec 31, 2021 | $10.65M | +37.3% | −$250.22M | −2,349.5% | −$36.80 | −$191.75M |
| FY2020ended Dec 31, 2020 | $7.76M | +1,080.5% | −$204.47M | −2,636.3% | −$313.80 | −$212.36M |
| FY2019ended Dec 31, 2019 | $657.00K | — | −$129.38M | −19,692.1% | −$480.80 | $23.43M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $4.00K | −$44.76M | −$1.92 |
| Q1 FY2026ended Mar 31, 2026 | $2.00K | −$24.15M | −$1.10 |
| Q4 FY2025ended Dec 31, 2025 | $6.00K | −$140.72M | −$7.50 |
| Q3 FY2025ended Sep 30, 2025 | $15.00K | −$38.85M | −$2.13 |
| Q2 FY2025ended Jun 30, 2025 | $8.00K | −$42.68M | −$2.89 |
| Q1 FY2025ended Mar 31, 2025 | $7.00K | −$52.20M | −$3.54 |
| Q4 FY2024ended Dec 31, 2024 | $11.00K | −$191.94M | −$14.36 |
| Q3 FY2024ended Sep 30, 2024 | $34.00K | −$44.58M | −$3.48 |
Company profile
- Name
- Lyell Immunopharma, Inc.
- Ticker
- LYEL
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 201 Haskins Way, South San Francisco, CA 94080
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001806952
Recent SEC filings
- Sep 10, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jun 15, 2026
- May 6, 2026
- May 6, 2026
- Mar 12, 2026
- Mar 12, 2026
Frequently asked questions
What is Lyell Immunopharma's stock price?
Lyell Immunopharma (LYEL) closed at $779.15 on Oct 9, 2026, up 0.82% from the previous close of $772.80.
What is Lyell Immunopharma's market cap?
Lyell Immunopharma's market cap is $18.23B, based on a share price of $779.15 and 23.4M shares outstanding as of Jun 30, 2026.
How much revenue does Lyell Immunopharma make?
Lyell Immunopharma reported revenue of $36.00K for fiscal 2025, down 40.98% from fiscal 2024.
Does Lyell Immunopharma pay a dividend?
Lyell Immunopharma's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Lyell Immunopharma, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures